United Therapeutics Co. (NASDAQ:UTHR) EVP Paul A. Mahon Sells 11,000 Shares

United Therapeutics Co. (NASDAQ:UTHR) EVP Paul A. Mahon sold 11,000 shares of the firm’s stock in a transaction on Thursday, April 17th. The stock was sold at an average price of $283.78, for a total value of $3,121,580.00. Following the sale, the executive vice president now owns 36,781 shares in the company, valued at $10,437,712.18. This trade represents a 23.02 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

United Therapeutics Trading Down 0.2 %

Shares of United Therapeutics stock opened at $284.73 on Friday. The company has a fifty day moving average price of $316.61 and a 200 day moving average price of $348.66. United Therapeutics Co. has a twelve month low of $233.28 and a twelve month high of $417.82. The stock has a market cap of $12.79 billion, a price-to-earnings ratio of 12.50, a price-to-earnings-growth ratio of 0.97 and a beta of 0.63.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.10 by $0.09. The business had revenue of $735.90 million during the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same quarter last year, the firm earned $4.36 earnings per share. Analysts forecast that United Therapeutics Co. will post 24.48 earnings per share for the current year.

Institutional Trading of United Therapeutics

A number of hedge funds have recently made changes to their positions in the company. MML Investors Services LLC acquired a new position in United Therapeutics in the 3rd quarter worth $245,000. World Investment Advisors LLC acquired a new position in shares of United Therapeutics in the third quarter worth about $393,000. Tidal Investments LLC boosted its holdings in United Therapeutics by 33.1% in the third quarter. Tidal Investments LLC now owns 11,272 shares of the biotechnology company’s stock valued at $4,039,000 after purchasing an additional 2,803 shares during the last quarter. Tri Ri Asset Management Corp purchased a new position in United Therapeutics in the third quarter valued at about $7,686,000. Finally, Franklin Resources Inc. grew its stake in United Therapeutics by 97.7% during the 3rd quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock valued at $89,532,000 after purchasing an additional 123,929 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on UTHR. UBS Group raised their price target on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $425.00 price target on shares of United Therapeutics in a research report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $388.25.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.